{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:45:25Z","timestamp":1790919925815,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T00:00:00Z","timestamp":1238630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T00:00:00Z","timestamp":1238630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1038\/leu.2009.60","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T09:55:51Z","timestamp":1238666151000},"page":"1500-1506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells"],"prefix":"10.1038","volume":"23","author":[{"given":"P","family":"Gamas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Puissant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Jacquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Colosetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-M","family":"Pasquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F-X","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-P","family":"Cassuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Auberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,2]]},"reference":[{"key":"BFleu200960_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0092-8674(00)80664-9","volume":"100","author":"J Schlessinger","year":"2000","unstructured":"Schlessinger J . New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000; 100: 293\u2013296.","journal-title":"Cell"},{"key":"BFleu200960_CR2","doi-asserted-by":"publisher","first-page":"7906","DOI":"10.1038\/sj.onc.1208160","volume":"23","author":"SJ Parsons","year":"2004","unstructured":"Parsons SJ, Parsons JT . Src family kinases, key regulators of signal transduction. Oncogene 2004; 23: 7906\u20137909.","journal-title":"Oncogene"},{"key":"BFleu200960_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/1074-7613(95)90126-4","volume":"3","author":"H Nishizumi","year":"1995","unstructured":"Nishizumi H, Taniuchi I, Yamanashi Y, Kitamura D, Ilic D, Mori S et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995; 3: 549\u2013560.","journal-title":"Immunity"},{"key":"BFleu200960_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1084\/jem.184.3.831","volume":"184","author":"J Wang","year":"1996","unstructured":"Wang J, Koizumi T, Watanabe T . Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J Exp Med 1996; 184: 831\u2013838.","journal-title":"J Exp Med"},{"key":"BFleu200960_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1074-7613(00)80511-7","volume":"7","author":"VW Chan","year":"1997","unstructured":"Chan VW, Meng F, Soriano P, DeFranco AL, Lowell CA . Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 1997; 7: 69\u201381.","journal-title":"Immunity"},{"key":"BFleu200960_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0092-8674(95)90171-X","volume":"83","author":"ML Hibbs","year":"1995","unstructured":"Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995; 83: 301\u2013311.","journal-title":"Cell"},{"key":"BFleu200960_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1074-7613(01)00208-4","volume":"15","author":"KW Harder","year":"2001","unstructured":"Harder KW, Parsons LM, Armes J, Evans N, Kountouri N, Clark R et al. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity 2001; 15: 603\u2013615.","journal-title":"Immunity"},{"key":"BFleu200960_CR8","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1038\/sj.onc.1209351","volume":"25","author":"BJ Lannutti","year":"2006","unstructured":"Lannutti BJ, Minear J, Blake N, Drachman JG . Increased megakaryocytopoiesis in Lyn-deficient mice. Oncogene 2006; 25: 3316\u20133324.","journal-title":"Oncogene"},{"key":"BFleu200960_CR9","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343\u20133356.","journal-title":"Blood"},{"key":"BFleu200960_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172\u2013183.","journal-title":"Nat Rev Cancer"},{"key":"BFleu200960_CR11","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1096\/fj.03-0322","volume":"17","author":"A Jacquel","year":"2003","unstructured":"Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, Pages G et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 2003; 17: 2160\u20132162.","journal-title":"FASEB J"},{"key":"BFleu200960_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189\u2013218.","journal-title":"Leukemia"},{"key":"BFleu200960_CR13","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1182\/blood-2003-12-4396","volume":"104","author":"KW Harder","year":"2004","unstructured":"Harder KW, Quilici C, Naik E, Inglese M, Kountouri N, Turner A et al. Perturbed myelo\/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Blood 2004; 104: 3901\u20133910.","journal-title":"Blood"},{"key":"BFleu200960_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/sj.onc.1208199","volume":"24","author":"E Ingley","year":"2005","unstructured":"Ingley E, McCarthy DJ, Pore JR, Sarna MK, Adenan AS, Wright MJ et al. Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis. Oncogene 2005; 24: 336\u2013343.","journal-title":"Oncogene"},{"key":"BFleu200960_CR15","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","volume":"66","author":"AK Samanta","year":"2006","unstructured":"Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB . Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006; 66: 6468\u20136472.","journal-title":"Cancer Res"},{"key":"BFleu200960_CR16","doi-asserted-by":"publisher","first-page":"33260","DOI":"10.1074\/jbc.272.52.33260","volume":"272","author":"M Warmuth","year":"1997","unstructured":"Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M . The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997; 272: 33260\u201333270.","journal-title":"J Biol Chem"},{"key":"BFleu200960_CR17","doi-asserted-by":"publisher","first-page":"30907","DOI":"10.1074\/jbc.M605902200","volume":"281","author":"MA Meyn III","year":"2006","unstructured":"Meyn III MA, Wilson MB, Abdi FA, Fahey N, Schiavone AP, Wu J et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006; 281: 30907\u201330916.","journal-title":"J Biol Chem"},{"key":"BFleu200960_CR18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/sj.cdd.4400400","volume":"5","author":"S Dan","year":"1998","unstructured":"Dan S, Naito M, Tsuruo T . Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR\u2013ABL tyrosine kinase, CGP 57148. Cell Death Differ 1998; 5: 710\u2013715.","journal-title":"Cell Death Differ"},{"key":"BFleu200960_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031\u20131037.","journal-title":"N Engl J Med"},{"key":"BFleu200960_CR20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038\u20131042.","journal-title":"N Engl J Med"},{"key":"BFleu200960_CR21","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530\u20133539.","journal-title":"Blood"},{"key":"BFleu200960_CR22","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu200960_CR23","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876\u2013880.","journal-title":"Science"},{"key":"BFleu200960_CR24","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690\u2013698.","journal-title":"Blood"},{"key":"BFleu200960_CR25","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1038\/sj.onc.1202782","volume":"18","author":"JE Ricci","year":"1999","unstructured":"Ricci JE, Maulon L, Luciano F, Guerin S, Livolsi A, Mari B et al. Cleavage and relocation of the tyrosine kinase P59FYN during Fas-mediated apoptosis in T lymphocytes. Oncogene 1999; 18: 3963\u20133969.","journal-title":"Oncogene"},{"key":"BFleu200960_CR26","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1096\/fj.00-0665fje","volume":"15","author":"JE Ricci","year":"2001","unstructured":"Ricci JE, Lang V, Luciano F, Belhacene N, Giordanengo V, Michel F et al. An absolute requirement for Fyn in T cell receptor-induced caspase activation and apoptosis. FASEB J 2001; 15: 1777\u20131779.","journal-title":"FASEB J"},{"key":"BFleu200960_CR27","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1038\/sj.onc.1204661","volume":"20","author":"F Luciano","year":"2001","unstructured":"Luciano F, Ricci JE, Auberger P . Cleavage of Fyn and Lyn in their N-terminal unique regions during induction of apoptosis: a new mechanism for Src kinase regulation. Oncogene 2001; 20: 4935\u20134941.","journal-title":"Oncogene"},{"key":"BFleu200960_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1096\/fj.02-0716fje","volume":"17","author":"F Luciano","year":"2003","unstructured":"Luciano F, Herrant M, Jacquel A, Ricci JE, Auberger P . The p54 cleaved form of the tyrosine kinase Lyn generated by caspases during BCR-induced cell death in B lymphoma acts as a negative regulator of apoptosis. FASEB J 2003; 17: 711\u2013713.","journal-title":"FASEB J"},{"key":"BFleu200960_CR29","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1038\/sj.onc.1210034","volume":"26","author":"A Jacquel","year":"2007","unstructured":"Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S et al. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene 2007; 26: 2445\u20132458.","journal-title":"Oncogene"},{"key":"BFleu200960_CR30","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","volume":"68","author":"FX Mahon","year":"2008","unstructured":"Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008; 68: 9809\u20139816.","journal-title":"Cancer Res"},{"key":"BFleu200960_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.onc.1209119","volume":"25","author":"A Jacquel","year":"2006","unstructured":"Jacquel A, Herrant M, Defamie V, Belhacene N, Colosetti P, Marchetti S et al. A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis. Oncogene 2006; 25: 781\u2013794.","journal-title":"Oncogene"},{"key":"BFleu200960_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1096\/fasebj.12.7.531","volume":"12","author":"N Belhacene","year":"1998","unstructured":"Belhacene N, Maulon L, Guerin S, Ricci JE, Mari B, Colin Y et al. Differential expression of the Kell blood group and CD10 antigens: two related membrane metallopeptidases during differentiation of K562 cells by phorbol ester and hemin. FASEB J 1998; 12: 531\u2013539.","journal-title":"FASEB J"},{"key":"BFleu200960_CR33","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1096\/fj.07-101394","volume":"22","author":"A Puissant","year":"2008","unstructured":"Puissant A, Grosso S, Jacquel A, Belhacene N, Colosetti P, Cassuto JP et al. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J 2008; 22: 1894\u20131904.","journal-title":"FASEB J"},{"key":"BFleu200960_CR34","doi-asserted-by":"publisher","first-page":"34227","DOI":"10.1074\/jbc.M402290200","volume":"279","author":"Y Dai","year":"2004","unstructured":"Dai Y, Rahmani M, Corey SJ, Dent P, Grant S . A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279: 34227\u201334239.","journal-title":"J Biol Chem"},{"key":"BFleu200960_CR35","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K et al. NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948\u20133954.","journal-title":"Blood"},{"key":"BFleu200960_CR36","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","volume":"111","author":"J Wu","year":"2008","unstructured":"Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008; 111: 3821\u20133829.","journal-title":"Blood"},{"key":"BFleu200960_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cancergencyto.2005.06.016","volume":"165","author":"C Sun","year":"2006","unstructured":"Sun C, Hu Y, Liu X, Wu T, Wang Y, He W et al. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 2006; 165: 9\u201319.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFleu200960_CR38","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1182\/blood-2006-02-003988","volume":"109","author":"A Bhardwaj","year":"2007","unstructured":"Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007; 109: 2293\u20132302.","journal-title":"Blood"},{"key":"BFleu200960_CR39","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/sj.leu.2401221","volume":"12","author":"C Shelly","year":"1998","unstructured":"Shelly C, Petruzzelli L, Herrera R . PMA-induced phenotypic changes in K562 cells: MAPK-dependent and -independent events. Leukemia 1998; 12: 1951\u20131961.","journal-title":"Leukemia"},{"key":"BFleu200960_CR40","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djn188","volume":"100","author":"J Wu","year":"2008","unstructured":"Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008; 100: 926\u2013939.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu200960_CR41","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","volume":"22","author":"F Luciano","year":"2003","unstructured":"Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G et al. Phosphorylation of Bim-EL by Erk1\/2 on Serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785\u20136793.","journal-title":"Oncogene"},{"key":"BFleu200960_CR42","doi-asserted-by":"publisher","first-page":"49511","DOI":"10.1074\/jbc.M208086200","volume":"277","author":"SC Biswas","year":"2002","unstructured":"Biswas SC, Greene LA . Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J Biol Chem 2002; 277: 49511\u201349516.","journal-title":"J Biol Chem"},{"key":"BFleu200960_CR43","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1073\/pnas.0606176103","volume":"103","author":"J Kuroda","year":"2006","unstructured":"Kuroda J, Puthalakah H, Gragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907\u201314912.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu200960.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu200960","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu200960.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:26:29Z","timestamp":1648729589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu200960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,2]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["BFleu200960"],"URL":"https:\/\/doi.org\/10.1038\/leu.2009.60","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,2]]},"assertion":[{"value":"11 August 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}